BMS’s Opdivo Flops in Phase 3 Lung-Cancer Study

Bristol-Myers Squibb revealed that Opdivo failed in a Phase 3 trial testing the drug’s efficacy as a monotherapy.

The trial failed to meet its endpoint of progression-free survival in patients with previously untreated advanced non-small cell lung cancer.

Beyond expressing disappointment in the results, company officials did not specify too what degree the drug failed.